Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration

One‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

“…A majority of the studies evaluated the VA change on ranibizumab therapy as a primary outcome, whereas several studies included VA change at 12 months as secondary outcomes. Eight studies were composed of multiple heterogeneous study groups, which were treated as individual study populations in this analysis . A majority of studies (73%) were observational, which was defined as single‐arm interventional designs and retrospective chart reviews (Table ).…”

“…Eight studies were composed of multiple heterogeneous study groups, which were treated as individual study populations in this analysis. 9,13,14,18,20,24,30,38 A majority of studies (73%) were observational, which was defined as single-arm interventional designs and retrospective chart reviews ( Table 1). The size of the study populations varied widely, ranging from 5 to 2324 patients, with a total of 10,444 patients included.…”

“…Of 51 study populations, 30 reported significant improvements in VA from baseline, 20 reported no statistical difference from baseline, and 1 reported a significant decrease from baseline, although this was a cohort of refractory patients whose results were reported separately from the study's nonrefractory population. 20 The meta-analysis showed an overall increase in VA at 12 months of 5.58 letters (95% confidence interval [CI]: 4.42-6.75 p heterogeneity, < 0.001) with ranibizumab treatment ( Table 2). When stratified by study type, 12-month improvements in VA were larger for RCTs, at 7.71 letters (95% CI: 6.66-8.76, p heterogeneity, 0.013), compared to observational studies, at 4.85 letters (95% CI: 3.32-6.38, p heterogeneity, < 0.001).…”

Optimal Management of Pigment Epithelial Detachments in Eyes With Neovascular Age-Related Macular Degeneration

“…A second prospective study evaluated 32 eyes with predominantly fibrovascular PED-type lesions secondary to nAMD that received intravitreal ranibizumab 0.5 mg injections monthly for 6 months. 9 At 6 months, eyes were stratified into responder (n = 24) and nonresponder (n = 5) groups according to visual acuity and spectral domain optical coherence tomography (SD-OCT) findings. Nonresponders did not receive further treatment, but were reevaluated at 12 months.…”

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set

“…Occurring in up to 62% eyes with advanced AMD, retinal pigment epithelial detachment (PED) is an important marker of disease severity and predictor of vision loss in AMD patients. 11 Although evidence from small, non-comparative studies suggests that both ranibizumab and aflibercept may be effective in reversing the anatomical changes associated with PED, 12 , 13 , 14 , 15 , 16 there is limited evidence of effectiveness in visual acuity outcomes in PED patients. 17 , 18 , 19 …”